Tempus AI, Inc. (NASDAQ: TEM), a leader in applying artificial intelligence to drive advancements in precision medicine and patient care, today announced that nine of its abstracts have been accepted for presentation at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting, scheduled to take place in Houston, Texas, from November 6-10, 2024.
“Presenting our latest research is an important opportunity to showcase how Tempus is advancing immunotherapy innovation through the power of data and AI,” said Ezra Cohen, MD, Chief Medical Officer of Oncology at Tempus. “We are committed to working alongside the oncology community to share insights that can help accelerate the development of personalized therapies and improve patient outcomes.”
Key Poster Presentations
Poster Presentation #188
Title: Clinical Validation of a Multi-Omic Algorithm for Stratifying Outcomes in Metastatic Solid Cancer Patients Treated with Immune Checkpoint Inhibitors
Session Date & Time: Saturday, November 9, 2024; 9:00 a.m. – 8:30 p.m. CT
Location: George R. Brown Convention Center, Exhibit Halls AB
Overview: This study introduces a novel approach for predicting patient outcomes to immune checkpoint inhibitors (ICI). By leveraging the Tempus multimodal real-world database, researchers developed and validated the Immune Profile Score (IPS) algorithm, which integrates DNA sequencing (xT) and RNA sequencing (xR). The IPS algorithm successfully stratified patient cohorts, offering a promising tool for prognosticating ICI treatment responses.
Poster Presentation #1352
Title: Impact of Real-World CT Imaging Timing on the Cost-Effectiveness of a Molecular Biomarker for Immunotherapy Treatment Response Monitoring
Session Date & Time: Saturday, November 9, 2024; 9:00 a.m. – 8:30 p.m. CT
Location: George R. Brown Convention Center, Exhibit Halls AB
Overview: This study examined how the timing of CT imaging influences the clinical utility and cost-effectiveness of a molecular biomarker used to monitor treatment responses in cancer patients receiving immune checkpoint inhibitors (ICI). Analysis of real-world imaging data from 4,147 advanced cancer patients revealed significant variation in CT scan intervals across different cancer types and treatments. A microsimulation model demonstrated that combining molecular biomarkers with CT imaging could lead to substantial cost savings and reduced inappropriate therapies, particularly in small cell lung cancer (SCLC) treated with ICI-chemotherapy.
About Tempus
Tempus is a technology company revolutionizing healthcare through artificial intelligence and precision medicine. With one of the largest multimodal data libraries globally, Tempus provides AI-powered tools to physicians, enabling personalized patient care and improving treatment outcomes. The company’s goal is to leverage the vast data it collects to inform better treatment decisions for each patient and drive the development of new therapeutics.
